尿细胞学诊断挑战:巴黎系统报告尿细胞学的实用见解
本文综述了尿细胞学在诊断高级别尿路上皮癌(HGUC)中的挑战,指出退行性改变、细胞稀少和反应性异型性可掩盖关键细胞学特征。巴黎系统通过标准化HGUC诊断标准提高了可重复性,但误分类风险仍存,尤其在评估细微异型性、组织碎片或退行性改变时。分子分型和人工智能驱动的细胞病理学有望增强可重复性和风险分层。
要点
- 尿细胞学是诊断HGUC和监测复发的重要工具,但退行性改变、细胞稀少和反应性异型性可干扰判读。
- 巴黎系统标准化了HGUC诊断标准,但区分HGUC与良性模仿病变仍是常见陷阱。
- 低级别尿路上皮肿瘤在排尿标本中不易脱落,且与反应性尿路上皮细胞难以区分,增加了风险分层难度。
核心结论
- 巴黎系统的目标是聚焦HGUC检测,以保持尿细胞学的特异性和阳性预测值。
- 尿细胞学的成功依赖于形态学专长、分子见解和临床数据的平衡整合。
研究设计与样本
- 本文为综述,探讨尿细胞学诊断挑战及巴黎系统的实用见解。
主要发现
- 退行性伪影、细胞稀少或反应性异型性可掩盖关键细胞学特征,使诊断复杂化。
- 区分HGUC与良性模仿病变(如长期尿液暴露、炎症或器械伪影)是常见陷阱。
- 非典型尿路上皮细胞的分类存在诊断灰色地带,其预测价值随临床背景变化很大。
- 低级别尿路上皮肿瘤在排尿标本中不常脱落,且可与反应性尿路上皮细胞无法区分。
临床怎么用
- 应用巴黎系统标准化标准诊断HGUC,以提高诊断可重复性。
- 整合形态学、分子和临床数据,以提高诊断准确性、减少误分类并优化患者管理。
- 关注退行性改变、组织碎片和反应性异型性等易误判因素。
局限性
- 误分类风险仍存,尤其在评估细微异型性、组织碎片或退行性改变时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Urinary cytology is an important tool for diagnosing high-grade urothelial carcinoma (HGUC) and plays a vital role in monitoring for disease recurrence. However, its diagnostic utility is often complicated by interpretive challenges, particularly when degenerative artifacts, sparse cellularity, or reactive atypia obscure key cytologic features. The Paris System for Reporting Urinary Cytology has significantly enhanced diagnostic reproducibility by establishing standardized criteria for the diagnosis of HGUC, but misclassification remains a risk, especially when evaluating subtle atypia, tissue fragments, or confounding factors like degenerative changes. One of the most frequent pitfalls in urinary cytology is differentiating HGUC from benign mimics, particularly in specimens affected by prolonged urine exposure, inflammation, or instrumentation artifacts. Similarly, the classification of atypical urothelial cells presents a diagnostic gray zone because its predictive value varies widely, depending on clinical context. Low-grade urothelial neoplasms further complicate risk stratification because these tumors infrequently exfoliate in voided specimens and can appear indistinguishable from reactive urothelial cells in these samples. Consequently, the goal of The Paris System for Reporting Urinary Cytology is to focus on the detection of HGUC to preserve the specificity and the positive predictive value of urinary cytology. Advancements in molecular profiling and artificial intelligence-driven cytopathology promise enhanced reproducibility and risk stratification, refining the role of urinary cytology in precision medicine. However, the success of urinary cytology remains rooted in a balanced approach, integrating morphologic expertise, molecular insights, and clinical data. By applying these essential practices, cytopathologists can improve diagnostic accuracy, reduce misclassification, and optimize patient management.
引用
- Allison DB, VandenBussche CJ. Diagnostic challenges in urinary cytology: Practical insights from The Paris System for Reporting Urinary Cytology. Cancer Cytopathol. 2025. PMID: 40762622. doi:10.1002/cncy.70033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。